Abstract：At present, the drug resistant tuberculosis is relatively high worldwide and has become a serious public health issue. New anti-tuberculosis drugs are urgently needed to prevent the increase of drug resistant tuberculosis. Bedaquiline and clofazimine are core anti-tuberculosis drugs belong to group A and B respectively, and are recommended by World Health Organization (WHO) for the treatment of multi-drug resistant tuberculosis with a good effect. However, Mycobacterium tuberculosis (MTB) that independent resistance and cross-resistance to bedaquiline and clofazimine gradually increased in recent years. This study reviewed the independent resistance and cross-resistance related genes of MTB to bedaquiline and clofazimine, with an emphasis on cross-resistant genes. At present, the gene mutation involved in bedaquiline and clofazimine cross-resistance to MTB are mainly Rv0678 (mmpR) and Rv2535c (pepQ) genes, which are non-target related mutation and result in lower-level cross-resistance to the two agents. The independent gene mutation involved in bedaquiline resistance is atpE, which is target related mutation. The independent gene mutation involved in clofazimine resistance is regarded as Rv1979c, although the drug resistant mechanisms is still not clear. The aim of this review is to provide a reference for the study on resistance mechanism of Mycobacterium tuberculosis to bedaquiline and clofazimine and for their further application on tuberculosis treatment.
王晓英, 罗明, 张汇征, 易利华. 结核分枝杆菌贝达喹啉和氯法齐明耐药及其交叉耐药机制研究进展[J]. 中国人兽共患病学报, 2022, 38(2): 165-169.
WANG Xiao-ying, LUO Ming, ZHANG Hui-zheng, YI Li-hua. Progress on the molecular mechanism of independent resistance and cross-resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Chinese Journal of Zoonoses, 2022, 38(2): 165-169.
[1] Lawn SD, Zumla AI.Tuberculosis[J]. Lancet, 2011, 378(9785): 57-72. DOI: 10.1016/S0140-6736(10)62173-3 [2] World Health Organization.Global tuberculosis report 2020[R]. Geneva: World Health Organization, 2020. [3] World Health Organization.WHO consolidated guidelines on drug-resistant tuberculosis treatment[M]. Geneva: World Health Organization, 2019. [4] World Health Organization.Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis[R]. Geneva: World Health Organization, 2020. [5] 厉娟, 聂理会, 唐神结. 贝达喹啉抗结核作用及其研究进展[J]. 中华医学杂志, 2015, 95(16): 1275-1277. DOI: 10.3760/cma.j.issn.0376-2491.2015.16.023 [6] Diacon AH, Pym A, Grobusch M, et al.The diarylquinoline TMC207 for multidrug-resistant tuberculosis[J]. N Engl J Med, 2009, 360(23): 2397-2405. DOI: 10.1056/NEJMoa0808427 [7] Lakshmanan M, Xavier AS.Bedaquiline-The first ATP synthase inhibitor against multi-drug resistant tuberculosis[J]. J Young Pharmacist, 2013, 5(4): 112-115. DOI: 10.1016/j.jyp.2013.12.002 [8] Goel D.Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis[J]. J Pharmacol Pharmacother, 2014, 5(1): 76-78. DOI: 10.4103/0976-500X.124435 [9] Islam MM, Hameed HM, Mugweru J, et al.Drug resistance mechanisms and novel drug targets for tuberculosis therapy[J]. J Genet Genomics, 2017, 44(1): 21-37. DOI: 10.1016/j.jgg.2016.10.002 [10] Hartkoorn RC, Uplekar S, Cole ST.Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2014, 58(5): 2979-2981. DOI: 10.1128/AAC.00037-14 [11] Cholo MC, Steel HC, Fourie PB, et al.Clofazimine: current status and future prospects[J]. J Antimicrob Chemother, 2012, 67(2): 290. DOI: 10.1093/jac/dkr444 [12] Yano Takahiro, Kassovska-Bratinova Sacha, Teh J Shin, et al.Reduction of clofazimine by mycobacterial type 2 NADH: quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species[J]. J Biol Chem, 2011, 286: 10276-10287. DOI: 10.1074/jbc.M110.200501 [13] Cholo MC, Boshoff HI, Steel HC, et al.Effects of clofazimine on potassium uptake by a Trk-deletion mutant of Mycobacterium tuberculosis[J]. J Antimicrob Chemother, 2006, 57(1): 79-84. DOI: 10.1093/jac/dki409 [14] Gopal M, Padayatchi N, Metcalfe JZ, et al.Systematic review of clofazimine for the treatment of drug-resistant tuberculosis[J]. Int J Tuberc Lung Dis, 2013, 17(8):1001-1007. [15] Swanson RV, Adamson J, Moodley C, et al.Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis[J]. Antimicrob Agents Chemother, 2015, 59(6): 3042-3051. DOI: 10.1128/AAC.00260-15 [16] Radhakrishnan A, Kumar N, Wright CC, et al.Crystal structure of the transcriptional regulator Rv0678 ofMycobacterium tuberculosis[J].J Biol Chem, 2014, 289(23):16526-16540. DOI: 10.1074/jbc.M113.538959 [17] Milano A, Pasca MR, Provvedi R, et al.Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system[J]. Tuberculosis, 2009, 89: 84-90. DOI: 10.1016/j.tube.2008.08.003 [18] Domenech P, Reed MB.Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance[J]. Infect Immun, 2005, 73(6): 3492. DOI: 10.1128/IAI.73.6.3492-3501.2005 [19] Pang Y, Zong Z, Huo F, et al.In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis from Beijing, China[J]. Antimicrob Agents Chemother, 2017, 61(10): e00900-17. DOI: 10.1128/AAC.00900-17 [20] Xu J, Wang B, Hu M, et al.Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis[J]. Antimicrob Agents Chemother, 2017, 61(6): e00239-17. DOI: 10.1128/AAC.00239-17 [21] Villellas C, Coeck N, Meehan CJ, et al.Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline[J]. J Antimicrob Chemother, 2017, 72: 684-690. DOI: 10.1093/jac/dkw502 [22] He W, Liu C, Liu D, et al. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China [J]. J Glob Antimicrob Resist, 2021, 29: S2213-7165(21)00160-0. DOI: 10.1016/j.jgar.2021.06.007 [23] Zheng H, He W, Jiao W, et al.Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China[J]. BMC Infect Dis, 2021, 21(1): 330. DOI: 10.1186/s12879-021-06024-8 [24] Somoskovi A, Bruderer V, Homke R, et al.A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment[J]. Eur Respir J, 2015, 45: 554-557. DOI: 10.1183/09031936.00142914 [25] Bloemberg GV, Keller PM, Stucki D, et al.Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis[J]. N Engl J Med, 2015, 373: 1986-1988. DOI: 10.1056/NEJMc1505196 [26] Liu Y, Gao J, Du J, et al.Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis[J]. Int J Infect Dis, 2021, 102: 392-396. DOI: 10.1016/j.ijid.2020.10.081 [27] Nimmo C, Millard J, van Dorp L, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis[J]. Lancet Microbe, 2020, 1(4): e165-e174. DOI: 10.1016/S2666-5247(20)30031-8 [28] Andries K, Villellas C, Coeck N, et al.Acquired resistance of Mycobacterium tuberculosis to bedaquiline[J]. PLoS One, 2014, 9(7): e102135. DOI: 10.1371/journal.pone.0102135 [29] Zhang S, Chen J, Cui P, et al.Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis[J]. J Antimicrob Chemother, 2015, 70(9): 2507-2510. DOI: 10.1093/jac/dkv150 [30] Almeida D, Ioerger T, Tyagi S, et al.Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2016, 60(8): 4590-4599. DOI: 10.1128/AAC.00753-16 [31] Andries K, Verhasselt P, Guillemont J, et al.A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis[J]. Science, 2005, 307: 223-227. DOI: 10.1126/science.1106753 [32] Petrella S, Cambau E, Chauffour A, et al.Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in Mycobacteria[J]. Antimicrob Agents Chemother, 2006, 50: 2853-2856. DOI: 10.1128/AAC.00244-06 [33] Huitric E, Verhasselt P, Koul A, et al.Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor[J]. Antimicrob Agents Chemother, 2010, 54: 1022-1028. DOI: 10.1128/AAC.01611-09 [34] Zimenkov DV, Nosova EY, Kulagina EV, et al.Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region[J]. J Antimicrob Chemother, 2017, 72: 1901-1906. DOI: 10.1093/jac/dkx094 [35] Ismail NA, Omar SV, Joseph L, et al.Defining bedaquiline susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective cohort study[J]. EBio Med, 2018, 28: 136-142. DOI: 10.1016/j.ebiom.2018.01.005 [36] Ismail N, Omar SV, Ismail NA, et al.In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants[J]. J Microbiol Methods, 2018, 3: 1-9. DOI: 10.1016/j.mimet.2018.08.011 [37] Phelan J, Coll F, McNerney R, et al. Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance[J]. BMC Med, 2016, 14: 31. DOI: 10.1186/s12916-016-0575-9
2022, Vol. 38 
